Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Value of Australia's BreastScreen programme confirmed

This article was originally published in Clinica

Executive Summary

The number of women in Australia being diagnosed with breast cancer is rising, according to a new report by the Australian Institute of Health and Welfare. However, according to BreastScreen Australia Monitoring Report 2003-2004, early detection and improved treatments have led to a 26% decrease in the mortality rate from breast cancer for women aged 50-69 (the age group for which free screening is provided every two years). In the 14 years to 2004, the death rate dropped by 2.1% per year, to 50.9 per 100,000 in 2004, whereas it stood at 68.5 per 100,000 in 1990. The incidence of invasive breast cancers in the target age group is high. In 2004, 3,851 invasive breast cancers were detected across all groups, of which 2,733 were found in women in the target age group.

You may also be interested in...



UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Wockhardt Preps To Deliver 100M Doses Of AZ Vaccine

As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies

ECHA Deliberates On Final Microplastic Proposal As Beauty Industry’s Fate Hangs In Balance

A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.

Topics

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel